178 related articles for article (PubMed ID: 38048644)
21. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease.
Ulanova M; Huska B; Desbiens A; Gaultier GN; Domonkos V; McCready WG
Vaccine; 2021 Jan; 39(4):699-710. PubMed ID: 33358702
[TBL] [Abstract][Full Text] [Related]
22. Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study.
Swarthout TD; Henrion MYR; Thindwa D; Meiring JE; Mbewe M; Kalizang'Oma A; Brown C; Msefula J; Moyo B; Mataya AA; Barnaba S; Pearce E; Gordon M; Goldblatt D; French N; Heyderman RS
Lancet Infect Dis; 2022 Dec; 22(12):1737-1747. PubMed ID: 36029796
[TBL] [Abstract][Full Text] [Related]
23. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
24. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.
Lewnard JA; Givon-Lavi N; Dagan R
Clin Infect Dis; 2020 Nov; 71(8):e289-e300. PubMed ID: 31784753
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology of Streptococcus pneumoniae causing acute otitis media among children in Southern Catalonia throughout 2007-2013: Incidence, serotype distribution and vaccine's effectiveness.
Ochoa-Gondar O; Figuerola-Massana E; Vila-Corcoles A; Aguirre CA; de Diego C; Satue E; Gomez F; Raga X;
Int J Pediatr Otorhinolaryngol; 2015 Dec; 79(12):2104-8. PubMed ID: 26453272
[TBL] [Abstract][Full Text] [Related]
26. 10-Valent pneumococcal non-typeable
Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
[TBL] [Abstract][Full Text] [Related]
27. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
28. Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia.
Takeshita K; Takeuchi N; Takahashi Y; Fukasawa C; Hishiki H; Hoshino T; Ishiwada N; Shimojo N
Hum Vaccin Immunother; 2021 Oct; 17(10):3687-3691. PubMed ID: 34213395
[TBL] [Abstract][Full Text] [Related]
29. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
Domínguez Á; Ciruela P; Hernández S; García-García JJ; Soldevila N; Izquierdo C; Moraga-Llop F; Díaz A; F de Sevilla M; González-Peris S; Campins M; Uriona S; Martínez-Osorio J; Solé-Ribalta A; Codina G; Esteva C; Planes AM; Muñoz-Almagro C; Salleras L
PLoS One; 2017; 12(8):e0183191. PubMed ID: 28806737
[TBL] [Abstract][Full Text] [Related]
32. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
35. Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland.
Allemann A; Frey PM; Brugger SD; Hilty M
Vaccine; 2017 Apr; 35(15):1946-1953. PubMed ID: 28279564
[TBL] [Abstract][Full Text] [Related]
36. Acute otitis media caused by Streptococcus pneumoniae serotype 19A ST320 clone: epidemiological and clinical characteristics.
Chi H; Chiu NC; Huang FY; Hsu CH; Lee KS; Huang LM; Hsieh YC
J Microbiol Immunol Infect; 2018 Jun; 51(3):337-343. PubMed ID: 28087317
[TBL] [Abstract][Full Text] [Related]
37. Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine.
Ulanova M; Huska B; Dubois S; McCready W
Vaccine; 2022 Jul; 40(32):4594-4602. PubMed ID: 35738971
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.
Kim DS; Shin SH; Lee HJ; Hong YJ; Lee SY; Choi KM; Oh CE; Kim KH; Juergens C; Patterson S; Giardina PC; Gruber WC; Emini EA; Scott DA
Pediatr Infect Dis J; 2013 Mar; 32(3):266-73. PubMed ID: 23011012
[TBL] [Abstract][Full Text] [Related]
39. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
[TBL] [Abstract][Full Text] [Related]
40. Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial.
Orami T; Aho C; Ford RL; Pomat WS; Greenhill A; Kirkham LA; Masiria G; Nivio B; Britton KJ; Jacoby P; Richmond PC; van den Biggelaar AHJ; Lehmann D
Vaccine; 2023 Aug; 41(37):5392-5399. PubMed ID: 37479616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]